Corporate GovernanceAug 7, 2026, 04:24 PM
CorMedix Derivative Lawsuit Settlement Gets Preliminary Approval
AI Summary
CorMedix Inc. announced that the U.S. District Court for the District of New Jersey granted preliminary approval for the proposed settlement of a consolidated derivative lawsuit and a related shareholder derivative action. The settlement resolves allegations that individual defendants breached fiduciary duties, leading to delayed FDA approval of DefenCath. It includes the implementation and maintenance of corporate governance reforms for at least three and a half years. A final settlement hearing is scheduled for September 23, 2026, and plaintiffs' counsel intends to seek up to $3.9 million in attorneys' fees.
Key Highlights
- Preliminary approval granted for derivative lawsuit settlement.
- Final settlement hearing scheduled for September 23, 2026.
- Settlement includes implementation of corporate governance reforms.
- Reforms to be maintained for a minimum period of 3.5 years.
- Plaintiffs' counsel to petition for up to $3.9 million in attorneys' fees.
- Lawsuit alleged individual defendants breached fiduciary duties.
- Allegations related to delayed FDA approval of DefenCath.
Price Impact
More from CRMD